Terms: = Lymphoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
767 results:
1. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
[TBL] [Abstract] [Full Text] [Related]
2. New treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
3. Outcome differences by sex in oncology clinical trials.
Kammula AV; Schäffer AA; Rajagopal PS; Kurzrock R; Ruppin E
Nat Commun; 2024 Mar; 15(1):2608. PubMed ID: 38521835
[TBL] [Abstract] [Full Text] [Related]
4. Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
Wang J; Ying J; Wang Z; Meng X; Wu M; Qian C
Ann Palliat Med; 2024 Mar; 13(2):221-229. PubMed ID: 38509647
[TBL] [Abstract] [Full Text] [Related]
5. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
6. Survival benefit in egfr-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
7. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
[TBL] [Abstract] [Full Text] [Related]
8. The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.
Lasala R; Romagnoli A; Santoleri F; Isgrò V; Confalonieri C; Costantini A; Enrico F; Russo G; Polidori P; Di Paolo A; Malorgio F; Beretta G; Musicco F
Eur J Clin Pharmacol; 2024 Apr; 80(4):519-527. PubMed ID: 38244052
[TBL] [Abstract] [Full Text] [Related]
9. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A; Ichihara E; Inoue K; Fujiwara K; Yokoyama T; Harada D; Ando C; Kano H; Oda N; Tamura T; Ochi N; Kawai H; Inoue M; Hara N; Fujimoto N; Ichikawa H; Oze I; Hotta K; Maeda Y; Kiura K
Int J Cancer; 2024 May; 154(9):1607-1615. PubMed ID: 38196128
[TBL] [Abstract] [Full Text] [Related]
10. Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report.
Yang Y; He X; Xiao W; Bai J; Liu Y
Anticancer Drugs; 2024 Mar; 35(3):292-297. PubMed ID: 38179893
[TBL] [Abstract] [Full Text] [Related]
11. Lovastatin treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria.
Gyoten M; Luo Y; Fujiwara-Tani R; Mori S; Ogata R; Kishi S; Kuniyasu H
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069135
[TBL] [Abstract] [Full Text] [Related]
12. erbb4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
13. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
14. Practical challenges in lung cancer pathology: bedside care to treatment decisions.
Takano AM; Chow CY; Lim KH
Curr Opin Pulm Med; 2024 Jan; 30(1):48-57. PubMed ID: 37937545
[TBL] [Abstract] [Full Text] [Related]
15. Circulating lung cancer biomarkers: From translational research to clinical practice.
Qian X; Meng QH
Tumour Biol; 2024; 46(s1):S27-S33. PubMed ID: 37927289
[TBL] [Abstract] [Full Text] [Related]
16. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through egfr activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of TP53 alterations in advanced NSCLC patients treated with egfr, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract] [Full Text] [Related]
18. [Mechanism of Astragali Radix-Curcumae Rhizoma in treating gastric cancer based on network pharmacology and experimental verification].
Tan XY; Tao J; Zhang Y; Gu RX
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):5056-5067. PubMed ID: 37802848
[TBL] [Abstract] [Full Text] [Related]
19. The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation.
Kępska-Dzilińska M; Karakulska-Prystupiuk E; Kaszyńska A; Basak GW; Małyszko J
Ren Fail; 2023; 45(2):2263581. PubMed ID: 37782282
[TBL] [Abstract] [Full Text] [Related]
20. RAGE potentiates egfr signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Liao WL; Lin H; Li YH; Yang TY; Chen MC
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
[TBL] [Abstract] [Full Text] [Related]
[Next]
